Background: The 2019 European Working Group on Sarcopenia in Older People (EWGSOP2) and the Sarcopenia Definitions and Outcomes Consortium (SDOC) have recently proposed sarcopenia definitions. However, comparisons of the performance of these approaches in terms of thresholds employed, concordance in individuals and prediction of important health-related outcomes such as death are limited. We addressed this in a large multinational assembly of cohort studies that included information on lean mass, muscle strength, physical performance and health outcomes.

Methods: White men from the Health Aging and Body Composition (Health ABC) Study, Osteoporotic Fractures in Men (MrOS) Study cohorts (Sweden, USA), the Hertfordshire Cohort Study (HCS) and the Sarcopenia and Physical impairment with advancing Age (SarcoPhAge) Study were analysed. Appendicular lean mass (ALM) was ascertained using DXA; muscle strength by grip dynamometry; and usual gait speed over courses of 2.4-6 m. Deaths were recorded and verified. Definitions of sarcopenia were as follows: EWGSOP2 (grip strength <27 kg and ALM index <7.0 kg/m ), SDOC (grip strength <35.5 kg and gait speed <0.8 m/s) and Modified SDOC (grip strength <35.5 kg and gait speed <1.0 m/s). Cohen's kappa statistic was used to assess agreement between original definitions (EWGSOP2 and SDOC). Presence versus absence of sarcopenia according to each definition in relation to mortality risk was examined using Cox regression with adjustment for age and weight; estimates were combined across cohorts using random-effects meta-analysis.

Results: Mean (SD) age of participants (n = 9170) was 74.3 (4.9) years; 5929 participants died during a mean (SD) follow-up of 12.1 (5.5) years. The proportion with sarcopenia according to each definition was EWGSOP2 (1.1%), SDOC (1.7%) and Modified SDOC (5.3%). Agreement was weak between EWGSOP2 and SDOC (κ = 0.17). Pooled hazard ratios (95% CI) for mortality for presence versus absence of each definition were EWGSOP2 [1.76 (1.42, 2.18), I : 0.0%]; SDOC [2.75 (2.28, 3.31), I : 0.0%]; and Modified SDOC [1.93 (1.54, 2.41), I : 58.3%].

Conclusions: There was low prevalence and poor agreement among recent sarcopenia definitions in community-dwelling cohorts of older white men. All indices of sarcopenia were associated with mortality. The strong relationship between sarcopenia and mortality, regardless of the definition, illustrates that identification of appropriate management and lifecourse intervention strategies for this condition is of paramount importance.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891989PMC
http://dx.doi.org/10.1002/jcsm.13160DOI Listing

Publication Analysis

Top Keywords

sarcopenia definitions
8
lean mass
8
muscle strength
8
sarcopenia
6
sarcopenia definitions-prevalence
4
definitions-prevalence agreement
4
agreement mortality
4
mortality associations
4
associations men
4
men findings
4

Similar Publications

Molecular mechanisms and therapeutic strategies of gut microbiota modulation in Sarcopenia (Review).

Oncol Lett

March 2025

Department of Geriatrics, Harbin 242 Hospital, Harbin, Heilongjiang 150060, P.R. China.

Sarcopenia is an age-related disease that is characterized by a decline in muscle mass and function with significant epidemiological and clinical implications. In recent years, gut microbiota has gained attention as an important regulatory factor in human health. To the best of our knowledge, this is the first study to introduce the definition and epidemiological background of sarcopenia and analyze the potential impact of the gut microbiota on muscle metabolism and growth, including aspects such as gut microbiota metabolites, muscle protein synthesis and energy metabolism.

View Article and Find Full Text PDF

Background: Most body composition research in individuals with Down Syndrome (DS) has focused on overweight and obesity. Although limited research has shown muscle mass indexes and physical performance levels of adults with DS are similar to or lower than older adults with sarcopenia, there is still a large gap in the literature regarding sarcopenia.

Objective: This brief report provides a comprehensive descriptive analysis of sarcopenia and obesity markers in individuals with DS.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates whether there is a causal relationship between sarcopenia (muscle loss) and cognitive impairment using a bidirectional Mendelian randomization approach, analyzing publicly available genetic data.
  • - Results showed that factors like appendicular lean mass, walking pace, and grip strength are linked to cognitive performance, and that cognitive performance can also influence these muscle factors.
  • - The findings support a clear cause-and-effect relationship between sarcopenia and cognitive impairment, highlighting the potential importance of muscle strengthening in preventing cognitive decline.
View Article and Find Full Text PDF

Objectives: To assess whether the effect of sarcopenia on neoadjuvant chemotherapy (NAC) toxicity is modified by borderline renal function (estimated glomerular filtration rate [eGFR] 40-65 mL/min) and whether sarcopenia and borderline renal function are independently associated with NAC toxicity risk.

Patients And Methods: All patients with muscle-invasive bladder cancer (MIBC) who underwent radical cystectomy (RC) between 2010 and 2022, with available cross-sectional imaging prior to NAC initiation, were included. Skeletal mass was measured from axial computed tomography images obtained at the level of the L3 vertebral body, using Aquarius Intuition software.

View Article and Find Full Text PDF

The prognostic significance of sarcopenia in patients treated with definitive radiotherapy: A systematic review.

Radiother Oncol

December 2024

The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.

Sarcopenia describes the degenerative loss of muscle mass and strength, and is emerging as a pan-cancer prognostic biomarker. It is linked with increased treatment toxicity, decreased survival and significant healthcare financial burden. Systematic analyses of sarcopenia studies have focused on outcomes in patients treated surgically or with systemic therapies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!